GetTopicDetailResponse(id=1a026e5053, topicName=Encorafenib, introduction=Encorafenib, content=null, image=null, comments=1, allHits=1516, url=https://h5.medsci.cn/topic?id=6750, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=59050, tagList=[TagDto(tagId=59050, tagName=Encorafenib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2269288, encodeId=13b022692882e, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#結(jié)直腸癌#</a> <a href='/topic/show?id=1a026e5053' target=_blank style='color:#2F92EE;'>#Encorafenib#</a>, objectTitle=NEJM：死亡風(fēng)險降低51%，無進(jìn)展生存期近乎翻倍！這類結(jié)直腸癌一線治療新突破, objectType=article, longId=882040, objectId=43c5882040bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240508/1715158312120_92910.png, objectUrl=/article/show_article.do?id=43c5882040bd, replyNumber=0, likeNumber=25, createdTime=2025-06-13, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=43c5882040bd, moduleTitle=NEJM：死亡風(fēng)險降低51%，無進(jìn)展生存期近乎翻倍！這類結(jié)直腸癌一線治療新突破, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=43c5882040bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2111268, encodeId=46c42111268c0, content=<a href='/topic/show?id=ddb3105120aa' target=_blank style='color:#2F92EE;'>#康奈非尼#</a>(<a href='/topic/show?id=1a026e5053' target=_blank style='color:#2F92EE;'>#Encorafenib#</a>)加<a href='/topic/show?id=2eaa9048456' target=_blank style='color:#2F92EE;'>#西妥昔單抗#</a>和化療對<a href='/topic/show?id=7755105121e7' target=_blank style='color:#2F92EE;'>#BRAF V600E#</a>突變型 <a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>安全和有效<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#結(jié)直腸癌#</a>，靶向治療能給患者帶來獲益，還要關(guān)注BRAF V600E突變治療后耐藥的新的突變類型, objectTitle=JCO：康奈非尼(Encorafenib)加西妥昔單抗和化療對BRAF V600E突變型 mCRC安全和有效（BREAKWATER試驗(yàn)）, objectType=article, longId=757114, objectId=0f98e5711425, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230123/1674499413115_4754896.png, objectUrl=/article/show_article.do?id=0f98e5711425, replyNumber=0, likeNumber=166, createdTime=2023-01-24, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0f98e5711425, moduleTitle=JCO：康奈非尼(Encorafenib)加西妥昔單抗和化療對BRAF V600E突變型 mCRC安全和有效（BREAKWATER試驗(yàn)）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0f98e5711425)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
